Commentary
Video
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Author(s):
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Dasom (Caroline) Lee, MD, Hematology and Medical Oncology Fellowship Program, Stanford Medicine, Stanford Health Care, discusses real-world early outcomes of treatment with second-line axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory large B-cell lymphoma. Lee and colleagues shared these results in a presentation at the 2024 ASH Annual Meeting.
Related Videos
Related Content
